Oui, les corticostéroïdes sont souvent prescrits pour réduire l'inflammation lors des poussées.
CorticostéroïdesInflammation
#3
Y a-t-il des traitements non médicamenteux ?
Oui, la rééducation physique et les thérapies complémentaires peuvent aider à gérer les symptômes.
Rééducation physiqueThérapies complémentaires
#4
Les traitements peuvent-ils arrêter la progression de la maladie ?
Certains traitements peuvent ralentir la progression, mais aucun ne guérit la maladie.
Progression de la maladieTraitements
#5
Comment les patients gèrent-ils les symptômes ?
Les patients utilisent souvent des stratégies de gestion du stress et des exercices adaptés.
Gestion du stressExercices adaptés
Complications
5
#1
Quelles sont les complications possibles de la maladie ?
Les complications incluent des infections, des problèmes de mobilité et des troubles psychologiques.
InfectionsTroubles psychologiques
#2
La sclérose en plaques peut-elle entraîner des handicaps ?
Oui, elle peut entraîner des handicaps physiques et cognitifs, affectant la vie quotidienne.
Handicaps physiquesVie quotidienne
#3
Les troubles urinaires sont-ils fréquents ?
Oui, de nombreux patients souffrent de troubles urinaires, affectant leur qualité de vie.
Troubles urinairesQualité de vie
#4
Comment la maladie affecte-t-elle la santé mentale ?
Elle peut entraîner des dépressions et de l'anxiété, nécessitant un suivi psychologique.
DépressionAnxiété
#5
Les complications peuvent-elles être gérées ?
Oui, un suivi médical régulier et des thérapies adaptées peuvent aider à gérer les complications.
Suivi médicalThérapies adaptées
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque ?
Les facteurs incluent l'âge, le sexe féminin, des antécédents familiaux et le tabagisme.
ÂgeAntécédents familiaux
#2
Le climat influence-t-il le risque de sclérose en plaques ?
Oui, les régions éloignées de l'équateur présentent un risque plus élevé de la maladie.
ClimatRisque
#3
Les infections virales sont-elles un facteur de risque ?
Certaines infections virales, comme le virus Epstein-Barr, sont associées à un risque accru.
Infections viralesVirus Epstein-Barr
#4
Le sexe joue-t-il un rôle dans le risque ?
Oui, les femmes sont plus susceptibles de développer la maladie que les hommes.
Sexe fémininRisque
#5
L'origine ethnique influence-t-elle le risque ?
Oui, certaines origines ethniques, comme les Caucasiens, présentent un risque plus élevé.
Origine ethniqueRisque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Sclérose en plaques récurrente-rémittente : Questions médicales les plus fréquentes",
"headline": "Sclérose en plaques récurrente-rémittente : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Sclérose en plaques récurrente-rémittente : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-28",
"dateModified": "2026-07-17",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Sclérose en plaques récurrente-rémittente"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Sclérose en plaques",
"url": "https://questionsmedicales.fr/mesh/D009103",
"about": {
"@type": "MedicalCondition",
"name": "Sclérose en plaques",
"code": {
"@type": "MedicalCode",
"code": "D009103",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C20.111.258.250.500"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Sclérose en plaques récurrente-rémittente",
"alternateName": "Multiple Sclerosis, Relapsing-Remitting",
"code": {
"@type": "MedicalCode",
"code": "D020529",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Jens Kuhle",
"url": "https://questionsmedicales.fr/author/Jens%20Kuhle",
"affiliation": {
"@type": "Organization",
"name": "Departments of Medicine, Biomedicine, and Clinical Research, Neurologic Clinic and Policlinic, University Hospital and University of Basel, Basel, Switzerland."
}
},
{
"@type": "Person",
"name": "Cavit Boz",
"url": "https://questionsmedicales.fr/author/Cavit%20Boz",
"affiliation": {
"@type": "Organization",
"name": "KTU Medical Faculty Farabi Hospital, Trabzon, Turkey."
}
},
{
"@type": "Person",
"name": "Serkan Ozakbas",
"url": "https://questionsmedicales.fr/author/Serkan%20Ozakbas",
"affiliation": {
"@type": "Organization",
"name": "Dokuz Eylul University, Konak/Izmir, Turkey."
}
},
{
"@type": "Person",
"name": "Murat Terzi",
"url": "https://questionsmedicales.fr/author/Murat%20Terzi",
"affiliation": {
"@type": "Organization",
"name": "Medical Faculty, 19 Mayis University, Samsun, Turkey."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset.",
"datePublished": "2023-10-13",
"url": "https://questionsmedicales.fr/article/37830451",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/13524585231202320"
}
},
{
"@type": "ScholarlyArticle",
"name": "Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.",
"datePublished": "2024-01-04",
"url": "https://questionsmedicales.fr/article/38174776",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD011381.pub3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis.",
"datePublished": "2023-08-29",
"url": "https://questionsmedicales.fr/article/37578431",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ene.16044"
}
},
{
"@type": "ScholarlyArticle",
"name": "Role of white matter in cognitive impairment among relapsing remitting multiple sclerosis patients.",
"datePublished": "2023-10-05",
"url": "https://questionsmedicales.fr/article/37837669",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.msard.2023.105030"
}
},
{
"@type": "ScholarlyArticle",
"name": "Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis.",
"datePublished": "2023-10-13",
"url": "https://questionsmedicales.fr/article/37833729",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12913-023-10099-1"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies du système immunitaire",
"item": "https://questionsmedicales.fr/mesh/D007154"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies auto-immunes",
"item": "https://questionsmedicales.fr/mesh/D001327"
},
{
"@type": "ListItem",
"position": 4,
"name": "Maladies auto-immunes du système nerveux",
"item": "https://questionsmedicales.fr/mesh/D020274"
},
{
"@type": "ListItem",
"position": 5,
"name": "Maladies démyélinisantes auto-immunes du SNC",
"item": "https://questionsmedicales.fr/mesh/D020278"
},
{
"@type": "ListItem",
"position": 6,
"name": "Sclérose en plaques",
"item": "https://questionsmedicales.fr/mesh/D009103"
},
{
"@type": "ListItem",
"position": 7,
"name": "Sclérose en plaques récurrente-rémittente",
"item": "https://questionsmedicales.fr/mesh/D020529"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Sclérose en plaques récurrente-rémittente - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Sclérose en plaques récurrente-rémittente",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-08-26",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Sclérose en plaques récurrente-rémittente",
"description": "Comment diagnostique-t-on la sclérose en plaques ?\nQuels tests sont utilisés pour confirmer le diagnostic ?\nQuels sont les signes cliniques de la sclérose en plaques ?\nLa sclérose en plaques peut-elle être confondue avec d'autres maladies ?\nQuel rôle joue l'IRM dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D020529#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Sclérose en plaques récurrente-rémittente",
"description": "Quels sont les symptômes courants de la sclérose en plaques ?\nLa douleur est-elle un symptôme fréquent ?\nComment la sclérose en plaques affecte-t-elle la mobilité ?\nLes symptômes varient-ils d'une personne à l'autre ?\nLes troubles cognitifs sont-ils possibles ?",
"url": "https://questionsmedicales.fr/mesh/D020529#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Sclérose en plaques récurrente-rémittente",
"description": "Peut-on prévenir la sclérose en plaques ?\nLe tabagisme influence-t-il le risque ?\nL'exposition au soleil a-t-elle un impact ?\nL'alimentation joue-t-elle un rôle ?\nLe stress peut-il aggraver la maladie ?",
"url": "https://questionsmedicales.fr/mesh/D020529#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Sclérose en plaques récurrente-rémittente",
"description": "Quels traitements sont disponibles pour la sclérose en plaques ?\nLes corticostéroïdes sont-ils utilisés ?\nY a-t-il des traitements non médicamenteux ?\nLes traitements peuvent-ils arrêter la progression de la maladie ?\nComment les patients gèrent-ils les symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D020529#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Sclérose en plaques récurrente-rémittente",
"description": "Quelles sont les complications possibles de la maladie ?\nLa sclérose en plaques peut-elle entraîner des handicaps ?\nLes troubles urinaires sont-ils fréquents ?\nComment la maladie affecte-t-elle la santé mentale ?\nLes complications peuvent-elles être gérées ?",
"url": "https://questionsmedicales.fr/mesh/D020529#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Sclérose en plaques récurrente-rémittente",
"description": "Quels sont les principaux facteurs de risque ?\nLe climat influence-t-il le risque de sclérose en plaques ?\nLes infections virales sont-elles un facteur de risque ?\nLe sexe joue-t-il un rôle dans le risque ?\nL'origine ethnique influence-t-elle le risque ?",
"url": "https://questionsmedicales.fr/mesh/D020529#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on la sclérose en plaques ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen neurologique, l'IRM et les tests de liquide céphalorachidien."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'IRM, l'électromyographie et l'analyse du liquide céphalorachidien."
}
},
{
"@type": "Question",
"name": "Quels sont les signes cliniques de la sclérose en plaques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des troubles de la vision, des engourdissements et des problèmes d'équilibre."
}
},
{
"@type": "Question",
"name": "La sclérose en plaques peut-elle être confondue avec d'autres maladies ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec d'autres maladies neurologiques comme la myélite transverse."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'IRM dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IRM permet de visualiser les lésions cérébrales et médullaires caractéristiques de la maladie."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de la sclérose en plaques ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, troubles de la vision, engourdissements et spasmes musculaires."
}
},
{
"@type": "Question",
"name": "La douleur est-elle un symptôme fréquent ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la douleur neuropathique est fréquente et peut affecter la qualité de vie."
}
},
{
"@type": "Question",
"name": "Comment la sclérose en plaques affecte-t-elle la mobilité ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut provoquer des troubles de la marche et une faiblesse musculaire, affectant la mobilité."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils d'une personne à l'autre ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes et leur intensité varient considérablement d'une personne à l'autre."
}
},
{
"@type": "Question",
"name": "Les troubles cognitifs sont-ils possibles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles de la mémoire et de la concentration peuvent survenir chez certains patients."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la sclérose en plaques ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention, mais un mode de vie sain peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il le risque ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque connu pour le développement de la maladie."
}
},
{
"@type": "Question",
"name": "L'exposition au soleil a-t-elle un impact ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une exposition adéquate au soleil peut réduire le risque en augmentant la vitamine D."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut soutenir la santé générale, mais son impact direct est incertain."
}
},
{
"@type": "Question",
"name": "Le stress peut-il aggraver la maladie ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut déclencher des poussées et aggraver les symptômes chez certains patients."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour la sclérose en plaques ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments immunomodulateurs et des thérapies symptomatiques."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils utilisés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les corticostéroïdes sont souvent prescrits pour réduire l'inflammation lors des poussées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements non médicamenteux ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la rééducation physique et les thérapies complémentaires peuvent aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Les traitements peuvent-ils arrêter la progression de la maladie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains traitements peuvent ralentir la progression, mais aucun ne guérit la maladie."
}
},
{
"@type": "Question",
"name": "Comment les patients gèrent-ils les symptômes ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients utilisent souvent des stratégies de gestion du stress et des exercices adaptés."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de la maladie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections, des problèmes de mobilité et des troubles psychologiques."
}
},
{
"@type": "Question",
"name": "La sclérose en plaques peut-elle entraîner des handicaps ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des handicaps physiques et cognitifs, affectant la vie quotidienne."
}
},
{
"@type": "Question",
"name": "Les troubles urinaires sont-ils fréquents ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreux patients souffrent de troubles urinaires, affectant leur qualité de vie."
}
},
{
"@type": "Question",
"name": "Comment la maladie affecte-t-elle la santé mentale ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner des dépressions et de l'anxiété, nécessitant un suivi psychologique."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être gérées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi médical régulier et des thérapies adaptées peuvent aider à gérer les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, le sexe féminin, des antécédents familiaux et le tabagisme."
}
},
{
"@type": "Question",
"name": "Le climat influence-t-il le risque de sclérose en plaques ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les régions éloignées de l'équateur présentent un risque plus élevé de la maladie."
}
},
{
"@type": "Question",
"name": "Les infections virales sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales, comme le virus Epstein-Barr, sont associées à un risque accru."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les femmes sont plus susceptibles de développer la maladie que les hommes."
}
},
{
"@type": "Question",
"name": "L'origine ethnique influence-t-elle le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines origines ethniques, comme les Caucasiens, présentent un risque plus élevé."
}
}
]
}
]
}
Departments of Medicine, Biomedicine, and Clinical Research, Neurologic Clinic and Policlinic, University Hospital and University of Basel, Basel, Switzerland.
Publications dans "Sclérose en plaques récurrente-rémittente" :
Neuroimmunology Group, Department of Medicine, University of Lleida-IRBLleida, Lleida, Spain Department of Neurology, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
Publications dans "Sclérose en plaques récurrente-rémittente" :
Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Neurology, The University Hospital Brno, Czech Republic. Electronic address: jan.kolcava1@gmail.com.
Publications dans "Sclérose en plaques récurrente-rémittente" :
Clinical relapses are the defining feature of relapsing forms of multiple sclerosis (MS), but relatively little is known about the time course of relapse recovery....
The aim of this study was to investigate the time course of and patient factors associated with the speed and success of relapse recovery in people with relapsing-remitting MS (RRMS)....
Using data from CombiRx, a large RRMS trial (clinicaltrials.gov identifier NCT00211887), we measured the time to recovery from the first on-trial relapse. We used Kaplan-Meier survival analyses and Co...
CombiRx included 1008 participants. We investigated 240 relapses. Median time to relapse recovery was 111 days. Most recovery events took place within 1 year of relapse onset: 202 of 240 (84%) individ...
Recovery from relapses takes place up to approximately 1 year after the event. Relapse severity, but no other patient factors, was associated with the speed of relapse recovery. Our findings inform cl...
Different therapeutic strategies are available for the treatment of people with relapsing-remitting multiple sclerosis (RRMS), including immunomodulators, immunosuppressants and biological agents. Alt...
To compare the efficacy and safety, through network meta-analysis, of interferon beta-1b, interferon beta-1a, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide, dimethyl fumarat...
CENTRAL, MEDLINE, Embase, and two trials registers were searched on 21 September 2021 together with reference checking, citation searching and contact with study authors to identify additional studies...
Randomised controlled trials (RCTs) that studied one or more of the available immunomodulators and immunosuppressants as monotherapy in comparison to placebo or to another active agent, in adults with...
Two authors independently selected studies and extracted data. We considered both direct and indirect evidence and performed data synthesis by pairwise and network meta-analysis. Certainty of the evid...
We included 50 studies involving 36,541 participants (68.6% female and 31.4% male). Median treatment duration was 24 months, and 25 (50%) studies were placebo-controlled. Considering the risk of bias,...
We are highly confident that, compared to placebo, two-year treatment with natalizumab, cladribine, or alemtuzumab decreases relapses more than with other DMTs. We are moderately confident that a two-...
In relapsing-remitting multiple sclerosis (RRMS), analyses from observational studies comparing dimethyl fumarate (DMF) and teriflunomide showed conflicting results. We aimed to compare the effectiven...
We included all patients who initiated DMF or teriflunomide between 2013 and 2022, listed in the Swiss National Treatment Registry. Coarsened exact matching was applied using age, gender, disease dura...
In total, 2028 patients were included in this study, of whom 1498 were matched (DMF: n = 1090, 69.6% female, mean age 45.1 years, median EDSS score 2.0; teriflunomide: n = 408, 68.9% female, mean age ...
Analysis of real-world data showed that DMF treatment was associated with more favorable outcomes than teriflunomide treatment....
Multiple Sclerosis (MS) associated cognitive impairment is believed to be mostly connected with damage to gray matter. The contribution of white matter is still poorly understood. We aim to examine th...
Thirty RRMS patients were selected undergo the (3-seconds-interstimulus-interval paced auditory serial addition test) PASAT-3, the (symbol digit modalities test (SDMT) and full-brain MRI scans on a SI...
The mean scores on the PASAT-3 and SDMT were 31.5 ± 12.8 and 46.9 ± 16.7 respectively. Better cognitive performance was correlated to higher FA values, while lower cognitive function was correlated to...
White matter tracts, particularly the superior cerebellar peduncle, contribute to the cognitive impairment in RRMS. Larger sample sizes for longitudinal research are necessary....
Multiple sclerosis is an inflammatory demyelination process in the central nervous system (CNS) causing neurological disability and poor quality of life. Currently, Thai Food and Drug Administration (...
This study aimed to evaluate the cost-utility and budget impact of rituximab for multiple sclerosis treatment compared with best supportive care, the standard practice in Thailand to treat the disease...
A rituximab biosimilar demonstrated higher effectiveness and lower associated costs, compared to best supportive care, with the highest probability of being cost-effective (96%). The probability of re...
In Thailand, a rituximab biosimilar would reduce the overall costs of multiple sclerosis treatment and should, therefore, be included in the National List of Essential Medicines....
Individualizing and optimizing treatment of relapsing-remitting multiple sclerosis patients is a challenging problem, which would benefit from a clinically valid decision support. Stühler et al. prese...
In patients from the French OFSEP registry, we independently built and validated models predicting being free of relapse and free of confirmed disability progression (CDP), following the methodologica...
The performance of our temporally-validated relapse model (MSE: 0.326, C-Index: 0.639) is potentially superior to that of Stühler's (MSE: 0.784, C-index: 0.608). Calibration plots revealed miscalibrat...
The relapse and CDP models rebuilt and externally validated in independent data could compare and strengthen the credibility of the Stühler models. Their model-building strategy was replicable....
Natalizumab is a monoclonal antibody used to treat patients with relapsing-remitting multiple sclerosis. Anemia is a recognized side effect, but it is usually mild and of a short duration when nataliz...
A 24 year-old Caucasian woman with relapsing-remitting multiple sclerosis developed severe transfusion dependent anemia after 27 infusions with natalizumab, which was her first and only treatment for ...
Severe anemia can be caused by treatment with natalizumab. This case adds information to the few other similar reported cases, demonstrating the potential duration of the anemia, as well as detailed d...
Multiple sclerosis (MS) is a common chronic autoimmune disease of the central nervous system. In MS, disability progresses unpredictably. Dopamine (DA) is a modulator of immune functions, and compelli...
Caucasian patients with relapsing-remitting (RR) MS were enrolled, and disease progression assessed by the Multiple Sclerosis Severity Score (MSSS)....
Out of the 59 RRMS patients enrolled, those with the G/G genotype for rs6280 and rs1800828 SNPs in DRD3 showed significantly higher MSSSs compared to those with ancestral and heterozygous genotypes....
If confirmed in a larger prospective study, the reported findings could contribute to a better understanding of MS pathophysiological mechanisms, opening the way for the identification of marker(s) fo...
Circulating microRNAs (MiRNAs) have been investigated for their role in fine-tuning the adaptive immune response to inflammatory factors and in Multiple Sclerosis (MS). They have been investigated as ...
A cross sectional study conducted at the MS centre of Foggia, Italy. We enrolled patients with (1) an age between 18 and 55 years, (2) a definitive diagnosis of relapsing remitting MS (RRMS) as per th...
A total cohort of 70 subjects (70% women) was analyzed. Out of them, 35 had a RRMS diagnosis. MiRNA 106a-5p (7.8 ± 3.8 vs 1.3 ± 0.9, p=0.03) had higher levels in RRMS patients when compared to OND. Th...
We described miRNA 106a-5p as a possible signature in the CSF of RRMS patients in early phases of the disease. Further studies are needed to characterize its role in early MS as a disease biomarker....
Relapsing-remitting multiple sclerosis (RRMS) is the most common phenotype of multiple sclerosis (MS), and its active stage is characterized by active T2 lesions with or without gadolinium (Gd) enhanc...
This retrospective, chart review study was conducted at a single center in Japan. The main study outcome was the yearly proportion of patients with active T2-weighted image lesions detected with or wi...
This study included data from 85 patients with RRMS who had received natalizumab for ≥ 1 year; of these, 65 (76.5%) were female and the mean ± standard deviation (SD) age at baseline was 37.5 ± 10.0 y...
The results of this first long-term study evaluating the effect of natalizumab on MRI activity and clinical outcomes in Japanese patients with RRMS suggest that natalizumab markedly reduced disease ac...
